Venlafaxine extended-release: A review of its use in the management of major depression

CNS Drugs

Volumn 15, Issue 8, 2001, Pages 643-669

  Wellington, K ^a   Perry, C M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CIMETIDINE; DESVENLAFAXINE; DIPHENHYDRAMINE; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY; ASTHENIA; BODY WEIGHT DISORDER; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DEPRESSION; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENTIATION; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; NEUROTOXICITY; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME; SUSTAINED RELEASE PREPARATION; UROGENITAL TRACT DISEASE; VISUAL DISORDER;

EID: 0034846803     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115080-00007     Document Type: Review

References (125)

1. Venlafaxine extended-release: A review of its clinical potential in the management of generalised anxiety disorder
2. Mechanism of action of antidepressant medications
3. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: A comparative study with paroxetine and desipramine
4. SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression
5. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression
6. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients
7. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression: Venlafaxine XR 208 Study Group
8. Venlafaxine: A review of its pharmacology and therapeutic potential in depression
9. Venlafaxine: A novel antidepressant compound
10. Venlafaxine: Pharmacology and therapeutic potential in the treatment of depression
11. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative
12. The pharmacology and mode of action of venlafaxine
13. Mechanisms of action and clinical characteristics of three atypical antidepressants: Venlafaxine, nefazodone, bupropion
14. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics
15. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans
16. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters
17. 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: Synthesis and antidepressant activity
18. Venlafaxine: Discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites
19. Lack of β adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine
20. Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers
21. Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression
22. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein
23. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers
24. The neuroendocrine effects of venlafaxine in healthy subjects
25. Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man
26. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol
27. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam
28. Venlafaxine's effects on healthy volunteers' driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens
29. Serotonin, noradrenaline and cognitive function: A preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor
30. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology
31. Effects of antidepressant drugs on sleep EEG in patients with major depression
32. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression
33. Effects of venlafaxine on sleep EEG during antidepressant treatment
34. Effects of venlafaxine in sleep of narcoleptic patients
35. Effexor XR (venlafaxine hydrochloride) extended release capsules
36. Cardiovascular and neurological toxicity of venlafaxine
37. Seizures associated with venlafaxine overdose
38. A case report of venlafaxine toxicity
39. Death from venlafaxine overdose (Effexor)
40. Coma, hypotension, and intraventricular block in a patient with venlafaxine and clonazepam overdose
41. Life-theatening hypotension from venlafaxine overdose
42. Seizures, ventricular tachycardia, and rhabdomyolysis as a result of ingestion of venlafaxine and lamotrigine
43. Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients
44. Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders
45. Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects
46. Pharmacokinetics of once-daily venlafaxine extended release in healthy volunteers
47. Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers
48. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine
49. Venlafaxine: A structurally unique and novel antidepressant
50. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite
51. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk
52. Venlafaxine oxidation in vitro is catalysed by CYP2D6
53. Venlafaxine-diphenhydramine interaction in subjects with extensive or poor CYP2D6 activity
54. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants
55. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population
56. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers
57. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man
58. Effect of venlafaxine on the pharmacokinetics of risperidone
59. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans
60. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations
61. Venlafaxine (VF): Effects on CYP2D6 dependent imipramine (IMP) and desipramine (DMP) 2-hydroxylation: Comparative studies with fluoxetine (FLU) and effects on CYP1A2, CYP3A4 and CYP2C9
62. Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms
63. Phenacetin O-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine
64. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine
65. Effect of venlafaxine on the pharmacokinetics of alprazolam
66. Effect of venlafaxine on the pharmacokinetics of terfenadine
67. The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine
68. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression: The Venlafaxine XR 209 Study Group
69. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
70. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice
71. Venlafaxine extended release is superior to placebo in relapse prevention for patients with major depressive disorder
72. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety: Venlafaxine XR 360 Study Group
73. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: A meta-analysis of randomized controlled trials
74. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
75. Comparative remission analysis between venlafaxine and paroxetine
76. A pharmacoeconomic evaluation of major depressive disorder
77. Breast enlargement during chronic antidepressant therapy
78. Safety and tolerance profile of venlafaxine
79. Cardiovascular safety in depressed patients: Focus on venlafaxine
80. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine
81. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine
82. The tolerability of venlafaxine hydrochloride
83. The safety and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database
84. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome
85. Serotonin syndrome from venlafaxine-tranylcypromine interaction
86. Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: Four patient reports
87. Serotonin syndrome induced by administration of venlafaxine and phenelzine
88. Serotonin syndrome secondary to phenelzine-venlafaxine interaction
89. Venlafaxine induced serotonin syndrome occurring after abstinence from phenehine for more than two weeks
90. Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy
91. Serotonin syndrome in combined moclobemide and venlafaxine ingestion
92. Venlafaxine-induced serotonin syndrome with relapse following amitriptyline
93. Isolated venlafaxine-induced serotonin syndrome
94. Practice guideline for the treatment of patients with major depressive disorder
95. Antidepressant discontinuation: A review of the literature
96. Withdrawal reactions associated with venlafaxine
97. Venlafaxine withdrawal reactions
98. Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine
99. Possible delayed venlafaxine withdrawal reaction: Two case reports
100. Venlafaxine withdrawal reactions
101. Treatment of venlafaxine discontinuation symptoms with ondansetron
102. Venlafaxine withdrawal syndrome
103. Venlafaxine withdrawal syndrome
104. The long-term treatment of depression
105. Status of treatment of depression
106. Strategies and tactics in the management of maintenance treatment for depressed patients
107. Treating major depression in primary care practice: An update of the Agency for Health Care Policy and Research Practice Guidelines
108. Population-based care of depression: Effective disease management strategies to decrease prevalence
109. Consensus statement on the primary care management of depression from the International Consensus Group on Depression and Anxiety
110. Long-term nature of depression
111. ASHP therapeutic position statement on the recognition and treatment of depression in older adults
112. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis
113. The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a Medicaid population
114. Rational drug use in the treatment of depression
115. Antidepressant options: Venlafaxine in perspective
116. The place for the tricyclic antidepressants in the treatment of depression
117. Is there an advantage to venlafaxine in comparison with other antidepressants?
118. North of England evidence-based guideline development project: Summary version of guidelines for the choice of antidepressants for depression in primary care
119. Drug treatment of depression
120. Antidepressant use in the elderly: Current status of nefazodone, venlafaxine and moclobemide
121. Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs